Some patients developed reduced levels of antibodies needed to ward off infection. This is treated with infusions of antibodies to displace the patients’ missing ones, Porter said. If the remissions observed in this scholarly study continue, and so far they have, it might be possible to take care of patients even earlier within their disease, Porter suggested. ‘As a one-period therapy, patients might not want repeated rounds of toxic chemotherapy, or prolonged treatment over many years to fight their malignancy. It really is early in the advancement of the approach still, but we are extremely optimistic about the potential,’ Porter said.The American Lung Association Asthma Clinical Research Centers are not bound by any confidentiality contract with regards to the study results. Statistical Analysis We calculated that with a sample size of 400 participants, the study could have 77 to 97 percent power, with a two-sided type I mistake price of 5 percent and 10 percent loss of data, to show a member of family difference of 33 percent in the proportion of participants having one or more episodes of poor asthma control, assuming a rate of 40 to 60 percent in the control group. The primary outcome was the price of episodes of poor asthma control; by basing the power calculation on the proportion of participants in each group who had one or more events, rather than on the function rate, we attained a conservative estimate of power.